Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative therapies function by mimicking the physiological actions of GLP-1, a hormone released by the gut in response to consumption. By activating GLP-1 receptors in the pancreas, these compounds enhance insulin secretion and r

The burgeoning landscape of innovative treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting substantial weight decrease – they exhibit intriguing contrasts